Elena Morrocchi (Italy)
Bambino Gesù Children Hospital Clinical Immunology and Vaccinology Research UnitAuthor Of 1 Presentation
PERINATALLY HIV-INFECTED ADOLESCENTS AND YOUNG ADULTS DEMONSTRATE DISTINCT BNT162B2 MRNA COVID-19 VACCINE IMMUNOGENICITY
Abstract
Backgrounds:
Immunization of vulnerable populations with distinct immunity often results in suboptimal immunogenicity, durability and efficacy.
Methods
To investigate the safety and the immunogenicity profiles of BNT162b2 mRNA COVID-19 vaccine among people living with HIV, we enrolled 28 HIV-infected patients under ART and 65 healthy controls (HCs) with no previous history of COVID-19. Immunogenicity was evaluated by measuring anti-RBD and anti-trimeric Abs, along with the frequency of SARS-CoV-2 specific CD4+CD40L+T cells. Samples were collected before vaccination (baseline, D0), at the second dose (D21), at 4 weeks (D28) and 6 months (D180) after the first dose. T and B cell phenotypes were investigated. Proteomic profiles at D0 and D28 were assessed with a Proximity Extension Assay (Olink) on plasma samples.
Results:
All vaccinated HIV-infected patients mounted anti-SARS-CoV-2 humoral responses between D21 and D28 similarly to HCs, albeit lower titers of anti-trimeric S Abs were detected at D28 compared to HC (p=0.0098). Only PBMCs of HIV+ demonstrated at D28 an impaired ability to expand their specific (CD40L+) CD4+ T populations. At 6 months, follow-up HIV+ showed similar maintenance of anti-SARS-CoV-2 Abs to HC. To explore whether these immunogenicity results could be linked to a particular proteomic outline, we correlated baseline protein levels to either humoral or cellular responses, identifying clusters of molecules involved in immune response regulation with inverse profiles between the two study groups.
Conclusions/Learning Points:
Responses of ART-treated HIV+ compared to HC, characterized by distinct features especially within the proteomic compartment, supporting their eligibility to an additional dose scheduled at 6 months, similarly to HC.
Presenter of 1 Presentation
PERINATALLY HIV-INFECTED ADOLESCENTS AND YOUNG ADULTS DEMONSTRATE DISTINCT BNT162B2 MRNA COVID-19 VACCINE IMMUNOGENICITY
Abstract
Backgrounds:
Immunization of vulnerable populations with distinct immunity often results in suboptimal immunogenicity, durability and efficacy.
Methods
To investigate the safety and the immunogenicity profiles of BNT162b2 mRNA COVID-19 vaccine among people living with HIV, we enrolled 28 HIV-infected patients under ART and 65 healthy controls (HCs) with no previous history of COVID-19. Immunogenicity was evaluated by measuring anti-RBD and anti-trimeric Abs, along with the frequency of SARS-CoV-2 specific CD4+CD40L+T cells. Samples were collected before vaccination (baseline, D0), at the second dose (D21), at 4 weeks (D28) and 6 months (D180) after the first dose. T and B cell phenotypes were investigated. Proteomic profiles at D0 and D28 were assessed with a Proximity Extension Assay (Olink) on plasma samples.
Results:
All vaccinated HIV-infected patients mounted anti-SARS-CoV-2 humoral responses between D21 and D28 similarly to HCs, albeit lower titers of anti-trimeric S Abs were detected at D28 compared to HC (p=0.0098). Only PBMCs of HIV+ demonstrated at D28 an impaired ability to expand their specific (CD40L+) CD4+ T populations. At 6 months, follow-up HIV+ showed similar maintenance of anti-SARS-CoV-2 Abs to HC. To explore whether these immunogenicity results could be linked to a particular proteomic outline, we correlated baseline protein levels to either humoral or cellular responses, identifying clusters of molecules involved in immune response regulation with inverse profiles between the two study groups.
Conclusions/Learning Points:
Responses of ART-treated HIV+ compared to HC, characterized by distinct features especially within the proteomic compartment, supporting their eligibility to an additional dose scheduled at 6 months, similarly to HC.